Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
ENDRA Life Sciences ( (NDRA) ) has issued an announcement.
On June 11, 2025, ENDRA Life Sciences Inc. shared an investor presentation on its website, detailing a new business strategy previously announced on March 31, 2025. This strategic update is part of the company’s ongoing efforts to enhance its market positioning and operational effectiveness.
The most recent analyst rating on (NDRA) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on ENDRA Life Sciences stock, see the NDRA Stock Forecast page.
Spark’s Take on NDRA Stock
According to Spark, TipRanks’ AI Analyst, NDRA is a Underperform.
ENDRA Life Sciences is currently facing significant financial and operational challenges, with no revenue generation and persistent losses. Despite some short-term technical momentum, the lack of profitability and unattractive valuation metrics weigh heavily on the stock’s potential. Immediate improvements in financial performance and strategic direction are crucial for enhancing its outlook.
To see Spark’s full report on NDRA stock, click here.
More about ENDRA Life Sciences
Average Trading Volume: 171,720
Technical Sentiment Signal: Sell
Current Market Cap: $2.58M
See more insights into NDRA stock on TipRanks’ Stock Analysis page.